Sysmex and QIAGEN Sign Exclusive Distribution Agreement for Infectious Disease and Oncology Diagnostics in Japan

Reuters

10/01

Sysmex and QIAGEN Sign Exclusive Distribution Agreement for Infectious Disease and Oncology Diagnostics in Japan

Sysmex Corporation has announced the signing of an exclusive agreement with QIAGEN N.V. for the distribution and supply of clinical diagnostic products related to infectious diseases and oncology in Japan. The agreement builds on a partnership between the two companies that has spanned more than ten years. Under the new strategic alliance, Sysmex will distribute QIAGEN's clinical diagnostic instruments and reagents, including leading products such as the QuantiFERON-TB Gold Plus test for tuberculosis and cancer molecular diagnostics. The companies also plan to explore joint research and development initiatives and may expand the range of products available in the Japanese market. This collaboration aims to enhance the delivery of clinical testing solutions and contribute to advancements in healthcare.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sysmex Corporation published the original content used to generate this news brief on October 01, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2572783585"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572783585\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572783585?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-01 14:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572783585","market":"nz","top_or_hot":-1,"title":"Sysmex and QIAGEN Sign Exclusive Distribution Agreement for Infectious Disease and Oncology Diagnostics in Japan","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sysmex and QIAGEN Sign Exclusive Distribution Agreement for Infectious Disease and Oncology Diagnostics in Japan\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sysmex Corporation has announced the signing of an exclusive agreement with QIAGEN N.V. for the distribution and supply of clinical diagnostic products related to infectious diseases and oncology in Japan. The agreement builds on a partnership between the two companies that has spanned more than ten years. Under the new strategic alliance, Sysmex will distribute QIAGEN's clinical diagnostic instruments and reagents, including leading products such as the QuantiFERON-TB Gold Plus test for tuberculosis and cancer molecular diagnostics. The companies also plan to explore joint research and development initiatives and may expand the range of products available in the Japanese market. This collaboration aims to enhance the delivery of clinical testing solutions and contribute to advancements in healthcare.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sysmex Corporation published the original content used to generate this news brief on October 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sysmex and QIAGEN Sign Exclusive Distribution Agreement for Infectious Disease and Oncology Diagnostics in Japan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSysmex and QIAGEN Sign Exclusive Distribution Agreement for Infectious Disease and Oncology Diagnostics in Japan\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-01 14:35</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sysmex and QIAGEN Sign Exclusive Distribution Agreement for Infectious Disease and Oncology Diagnostics in Japan\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sysmex Corporation has announced the signing of an exclusive agreement with QIAGEN N.V. for the distribution and supply of clinical diagnostic products related to infectious diseases and oncology in Japan. The agreement builds on a partnership between the two companies that has spanned more than ten years. Under the new strategic alliance, Sysmex will distribute QIAGEN's clinical diagnostic instruments and reagents, including leading products such as the QuantiFERON-TB Gold Plus test for tuberculosis and cancer molecular diagnostics. The companies also plan to explore joint research and development initiatives and may expand the range of products available in the Japanese market. This collaboration aims to enhance the delivery of clinical testing solutions and contribute to advancements in healthcare.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sysmex Corporation published the original content used to generate this news brief on October 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科學工具和服務","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL4DHLYj:1","article_id":"2572783585","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572783585","pubTimestamp":1759300543,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sysmex Corporation has announced the signing of an exclusive agreement with QIAGEN N.V. for the distribution and supply of clinical diagnostic products related to infectious diseases and oncology in Japan. The agreement builds on a partnership between the two companies that has spanned more than ten years. Under the new strategic alliance, Sysmex will distribute QIAGEN's clinical diagnostic instruments and reagents, including leading products such as the QuantiFERON-TB Gold Plus test for tuberculosis and cancer molecular diagnostics. The companies also plan to explore joint research and development initiatives and may expand the range of products available in the Japanese market. This collaboration aims to enhance the delivery of clinical testing solutions and contribute to advancements in healthcare.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","QGEN":"快而精医药","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD"},"translate_title":"Sysmex与QIAGEN签署日本传染病和肿瘤诊断独家经销协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QGEN":0.9},"content_text":"Sysmex and QIAGEN Sign Exclusive Distribution Agreement for Infectious Disease and Oncology Diagnostics in Japan\n    \n\n        Sysmex Corporation has announced the signing of an exclusive agreement with QIAGEN N.V. for the distribution and supply of clinical diagnostic products related to infectious diseases and oncology in Japan. The agreement builds on a partnership between the two companies that has spanned more than ten years. Under the new strategic alliance, Sysmex will distribute QIAGEN's clinical diagnostic instruments and reagents, including leading products such as the QuantiFERON-TB Gold Plus test for tuberculosis and cancer molecular diagnostics. The companies also plan to explore joint research and development initiatives and may expand the range of products available in the Japanese market. This collaboration aims to enhance the delivery of clinical testing solutions and contribute to advancements in healthcare.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sysmex Corporation published the original content used to generate this news brief on October 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}